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AMP-activated protein kinase (AMPK) is a heterotrimeric
complex, composed of a catalytic subunit () and two regulatory
subunits ( and ), that works as a cellular energy sensor. The
existence of multiple heterotrimeric complexes provides a
molecular basis for the multiple roles of this highly conserved
signaling system. The AMPK 3 subunit is predominantly
expressed in skeletal muscle, mostly in type II glycolytic fiber
types. We determined whether the AMPK 3 subunit has a role
in signaling pathways that mediate mitochondrial biogenesis in
skeletal muscle. We provide evidence that overexpression or
ablation of the AMPK 3 subunit does not appear to play a crit-
ical role in defining mitochondrial content in resting skeletal
muscle. However, overexpression of a mutant form (R225Q) of
the AMPK 3 subunit (Tg-AMPK3225Q) increases mitochon-
drial biogenesis in glycolytic skeletal muscle. These adaptations
are associated with an increase in expression of the co-activator
PGC-1 and several transcription factors that regulate mito-
chondrial biogenesis, includingNRF-1,NRF-2, andTFAM. Suc-
cinate dehydrogenase staining, a marker of the oxidative profile
of individual fibers, was also increased in transversal skeletal
muscle sections of white gastrocnemius muscle from
Tg-AMPK3225Q mice, independent of changes in fiber type
composition. In conclusion, a single nucleotide mutation
(R225Q) in the AMPK 3 subunit is associated with mitochon-
drial biogenesis in glycolytic skeletal muscle, concomitant with
increased expression of the co-activator PGC-1 and several
transcription factors that regulate mitochondrial proteins,
without altering fiber type composition.
Skeletal muscle is a heterogeneous tissue that is composed of
different fiber types, which are characterized by distinct con-
tractile andmetabolic properties. Skeletal muscle adapts to dif-
ferent conditions that require quick or long term alterations in
power, force production, or substrate availability and utiliza-
tion. Regular endurance exercise training promotes mitochon-
drial biogenesis (1) through an orchestrated change in the
expression of genes that encode mitochondrial proteins (2).
The AMPK2 pathway plays a major role in the physiological
regulation of mitochondrial function and biogenesis (3–8) and
has been suggested to prevent or reverse peripheral insulin
resistance associated with Type 2 diabetes (9–11).
AMPK is a cellular energy sensor that is activated in response
to an increase in the AMP/ATP ratio. Once activated, AMPK
coordinates signaling events to initiate catabolic processes that
increase energy production and terminate anabolic processes,
such as protein synthesis. AMPK activation modulates tran-
scription of specific genes involved in energy metabolism,
thereby exerting long termmetabolic control. AMPK exists as a
heterotrimeric complex composed of a catalytic () and two
regulatory ( and ) subunits. The - and -subunits are each
encoded by two genes (1, 2, 1, and 2), and the  subunit is
encoded by three genes (1, 2, and 3), yielding 12 possible
heterotrimeric complexes. In human skeletal muscle, only
three (121, 221, and 223) of the 12 AMPK com-
plexes are present (12). The existence of multiple heterotri-
meric complexes provides a molecular basis for the multiple
roles of this highly conserved signaling system in nutrient reg-
ulation and utilization in mammalian cells (13).
Exercise activates AMPK (11) and induces skeletal muscle
mitochondrial biogenesis (14), but the mechanism is incom-
pletely resolved. Molecular approaches using transgenic or
knock-out technology that targets AMPK subunit isoforms
provide direct evidence for specific signal transducers in medi-
ating mitochondrial biogenesis. The AMPK 3 subunit is pre-
dominantly expressed in glycolytic skeletal muscle (15–20).
Transgenic expression of the R225Q mutation in mice (Tg-
AMPK3225Q mice) is associated with increased skeletal mus-
cle glycogen content, fatigue resistance, and protection from
diet-induced insulin resistance through increased -oxidation
(17). These metabolic responses in sedentary Tg-AMPK3225Q
mimic the effects of exercise training and are partly mediated
through transcriptional regulation of genes important for gly-
colytic and oxidative metabolism (20). However, the role of the
AMPK 3 subunit, as well as whethermutations in this isoform
regulate mitochondrial biogenesis and function in resting skel-
etal muscle, is unresolved.
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Here we determined the role of the AMPK 3 subunit in the
regulation of mitochondrial function and biogenesis in glyco-
lytic skeletal muscle. Three mouse models were used to genet-
ically dissect the functional role of the AMPK3 isoform: trans-
genic mice overexpressing either the wild-type or the R225Q
mutant subunit (Tg-AMPK3wt or Tg-AMPK3225Q) and
knock-out mice (AMPK3/). We provide evidence that the
mutant form of the AMPK 3 subunit influences gene expres-
sion, promoting adaptive metabolic responses on mitochon-
drial function and biogenesis in skeletal muscle. Therefore, the
AMPK 3 subunit may play a critical role in mediating the
metabolic adaptations in glycolytic skeletal muscle in response
to cellular stress and energy deficiency.
EXPERIMENTAL PROCEDURES
Reagents for denaturing electrophoresis (SDS-PAGE) and
Western blot analysis were from Bio-Rad. Reagents for
enhanced chemiluminescence (ECL) were purchased from
Amersham Biosciences. Mouse anti-human monoclonal anti-
bodies against NADH ubiquinol oxidoreductase 39-kDa sub-
unit (Complex I), succinate-ubiquinol oxidoreductase 70-kDa
subunit (Complex II), ubiqinol-cytochrome c oxidoreductase
subunits I (Complex III), cytochrome oxidase subunit I (Com-
plex IV), and ATP synthase subunit  were obtained from
Molecular Probes, Inc. (Eugene,OR).Mouse anti-cytochrome c
monoclonal antibody was purchased from PharMingen Inter-
national (San Diego, CA). Polyclonal rabbit anti-humanUCP-3
(uncoupling protein 3) and anti-mouse PGC-1 (peroxisome
proliferator  co-activator-1) antibodies were purchased from
Chemicon International (Temecula, CA). Polyclonal goat anti-
mouse NRF-1 (nuclear respiratory factor 1) and TFAM (mito-
chondrial transcription factor A) were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Horseradish perox-
idase-conjugated donkey anti-rabbit, donkey anti-goat, and
goat anti-mouse IgG were purchased from Jackson Immuno-
Research Laboratories (West Grove, PA). Rat IgGwas obtained
from Santa Cruz Biotechnology. Myosin heavy chain (MyHC)
type IIa (SC-71) andMyHC type I (D-5) antibodies were kindly
donated by Professor Stefano Schiaffino. TRIzol reagent for iso-
lation of RNA was purchased from Invitrogen. Reagents for
isolation of mRNA were obtained from Ambion (Austin, TX).
TaqMan reverse transcription and RT-PCR reagents were pur-
chased from Applied Biosystems (Foster City, CA). All other
reagents were obtained from Sigma.
Animal Care—This research was approved by the regional
animal ethical committee. Animals were maintained in a tem-
perature- and light-controlled environment and were cared for
in accordance with regulations for the protection of laboratory
animals. Animals were maintained under a 12-h light/dark
cycle and had free access to water and standard rodent chow.
Three different mouse models were used to investigate the role
of the skeletal muscle specific AMPK 3 subunit in the regula-
tion of mitochondrial function and mitochondrial biogenesis:
AMPK 3 knock-out (AMPK3/), AMPK 3 wild-type
transgenic (Tg-AMPK3wt), and AMPK 3R225Q transgenic
(Tg-AMPK3225Q). The mouse models used in this study
have been described previously (17). The AMPK3/ mice
were created by conventional gene targeting techniques.
Tg-AMPK3wt and Tg-AMPK3225Q mice express the wild-
type 3 subunit or the R225Q mutant 3 subunit under the
control of mouse myosin-light chain promoter and enhancer
elements. All three models used in the study were bred into a
C57BL/6 genetic background. Transgenicmice were compared
with nontransgenic littermates. Knock-out homozygote mice
were compared with homozygous wild-type littermates. In our
initial characterization of these models (17), we reported a
marked overexpression of the wild-type transgene in extensor
digitorum longus (EDL), gastrocnemius, and quadriceps mus-
cle (16.5-, 6.6-, and 1.7-fold, respectively), but no overexpres-
sion or only amoderate overexpression of themutant transgene
(0.7-, 1.0-, and 1.8-fold, respectively). The differences in the
level of expression between the two transgenic mice may be
explained by positional effects or number of integrated copies.
We also reported that the levels of endogenous AMPK3
transcript in Tg-AMPK3225Q mice tended to be decreased
(17). Furthermore, the amount of expressed 3 protein, as
well as , , or the other  subunits, was unchanged, in the
Tg-AMPK3225Q mice (17). Thus, AMPK expression in
Tg-AMPK3225Qmice appears to resemble the expression pat-
tern in nontransgenic wild-type mice, both in regard to tissue
distribution and protein expression. Themutant form (R225Q)
presumably replaced endogenous 3, based on the relative
mRNA expression (17). However, endogenous and exogenous
forms of the protein, as assessed byWestern blot analysis, were
indistinguishable (17), since they differed by a single amino acid
substitution. Mice were anesthetized with an intraperitoneal
injection of Avertin (2,2,2-tribromoethanol (99%) and tertiary
amyl alcohol (0.015–0.017 ml/g body weight), intraperitone-
ally), and the white portion of the gastrocnemius muscle was
dissected and cleaned of fat and blood and snap-frozen in liquid
nitrogen.
Quantitative PCR—Quantification of mRNA was performed
using real-time PCR as described (18). Total RNA isolated from
the white portion of the gastrocnemius muscle was reverse tran-
scribed with oligo(dT) primers using the SuperScript First Strand
SynthesisSystem(Invitrogen).Reactionswereperformed indupli-
cate in a96-well formatusingaPrism7000SequenceDetector and
fluorescence-based SYBR-green technology (Applied Biosys-
tems). Mouse-specific primer/probe sets used to detect specific
gene expression were selected by using PRIMER EXPRESS
(Applied Biosystems) and are available upon request. The follow-
ing primers for detection of the different myosin heavy chain iso-
formswere used:MyHC I forward (TTGTGCTACCCAGCTCT-
AAGGG) and reverse (CTGCTTCCACCTAAAGGGCTG);
MyHC IIa forward (AAGCGAAGAGTAAGGCTGTC) and
reverse (CTTGCAAAGGAACTTGGGCTC);MyHC IIb forward
(GAAGAGCCGAGAGGTTCACAC) and reverse (CAGGACA-
GTGACAAAGAACGTC); andMyHC IIx forward (GAAGAGT-
GATTGATCCAAGTG) and reverse (TATCTCCCAAAGTTA-
TGAGTACA). Relative quantities of target transcripts were
calculated after normalization against a housekeeping gene (acidic
ribosomal phosphoprotein PO) using the relative standard curve
method.
Muscle Lysate Preparation and Western Blot Analysis—
White gastrocnemius muscles were homogenized in ice-cold
buffer (10% (v/v) glycerol, 20 mM sodium pyrophosphate, 150
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mM NaCl, 50 mM HEPES (pH 7.5), 1% Nonidet P-40, 20 mM
-glycerophosphate, 10 mM sodium fluoride, 1 mM EDTA, 1
mM EGTA, 2 mM phenylmethylsulfonyl fluoride, 10 g/ml
aprotinin, 10 g/ml leupeptin, 2 mM sodium orthovanadate,
and 3 mM benzamidine (pH 7.4)). Whole muscle homogenates
were rotated end-over-end for 1 h at 4 °C and then subjected to
three freeze and thaw cycles to disrupt the mitochondria. The
homogenates were centrifuged at 10,000  g for 15min at 4 °C,
and the supernatant was collected. Protein concentration was
measured using a BCA protein assay kit, and sample dilutions
were adjusted to yield equal protein concentration. Aliquots for
Western blot analysis were mixed with Laemmli buffer, sepa-
rated by SDS-PAGE, and transferred to polyvinylidene difluo-
ride membranes. The membranes were blocked overnight at
4 °C with 5% nonfat dry milk in Tris-buffered saline containing
0.1% (v/v) Tween. The blots were probed with primary anti-
body, followed by incubation with the appropriate horseradish
peroxidase-conjugated anti-IgG antibody. Antibody-bound
protein was detected using enhanced chemiluminescence and
quantified by densitometry.
Quantification of Mitochondrial DNA Copy Number—To
determine mitochondrial DNA levels, total genomic DNA was
isolated from white gastrocnemius, and the amount of mito-
chondrial DNA (mtDNA) was compared with nuclear DNA.
Primers for mtDNA (cytochrome b; forward, AAAGCCACC-
TTGACCCGATT; reverse, GATTCGTAGGGCCGCGATA;
Custom TaqMan TAMRATM probe, CGCTTTCCACTTC-
ATCTTACCATT), nuclear DNA (mouse -actin), and 1
TaqMan Universal PCR Master Mix were supplied by Applied
Biosystems. Real time PCR quantitative analysis was performed
using CT on the sequence detector system ABI-Prism 7000.
Copy number of mtDNA and nuclear DNA was calculated
using the threshold cycle number (CT) intrapolated from the
standard curve.
Histological Methods—Gastrocnemius, plantaris, soleus,
and EDL muscles were harvested and frozen together in Tis-
sue-Tek O.C.T.TM compound (Tissue-Tek, Sakura Finetek
Europe, Zoeterwoude, Netherlands). Serial skeletal muscle
cross-sections (10 m for fiber type measurement, immuno-
staining, and succinate dehydrogenase (SDH) staining) were
generated in a Microstat HM 500M cryostat, mounted on
SuperFrost slides (Menzel GmbH&Co., Braunschweig, Ger-
many) and stored at 20 °C until use. Skeletal muscle fiber
type (I, IIa, and IIb) was quantified using myosin ATPase
staining (21). Sections were subjected to acidic preincuba-
tion (0.2 M sodium acetate, 0.1 M KCl, pH 4.43), incubated
with ATP (90 mM glycine, 65 mM CaCl2, 90 mM NaCl, 3 mM
ATP, pH 9.4), and subsequently treated with 1% (w/v) CaCl2,
2% (w/v) CoCl2, and 1% (v/v) (NH4)2S. Immunostaining was
performed with MyHC type IIa (SC-71) and MyHC type I
(D-5) antibodies, as directed by the M.O.M.TM kit (Vector
Laboratories, Burlingame, CA). SDH staining was performed
by treatment with incubation solution (6.5 mM NaH2PO4,
43.5 mM Na2HPO4, 0.6 mM nitro blue tetrazolium, and 50
mM sodium succinate, pH 7.6), followed by treatment with
physiological saline and 15% ethanol. Following histological
procedures, coverslips were secured over the slides with
aqueous mounting medium (Dako, Glostrup, Denmark).
Image Capture and Analysis—Images for fiber type analysis
were captured using an Olympus DP70 camera (Olympus
Corp., Japan) and Cast software (Visiopharm, Horsholm, Den-
mark). Quantification of the fiber type composition was per-
formed using Image J version 1.37 (National Institutes of
Health). Fiber type identificationwasmade using threshold val-
ues of particle density: type I fibers40, type IIa210, and type
IIb210. An average of 100 fibers/musclewas counted, and the
percentage of each fiber type per muscle was calculated.
Electrophoretic Separation of MyHC Isoforms—White gas-
trocnemius muscle was dissected and homogenized in lysis
buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.5 mM
Na3VO4, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 20 mM Tris
(pH 7.8), 1 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluo-
ride, 10 mM NaF, 1 g/ml aprotinin, 1 mM EDTA, 5 mM pyro-
phosphate, and 1Mmicrocystin), and 50l was removed prior
to centrifugation. Total protein content was assessed using a
BCA assay. Electrophoretic separation of MyHC isoforms was
performed as described (22). Whole muscle homogenate was
separated on a glycerol SDS-polyacrylamide gel (stacking gel:
4% (v/v) acrylamide (40:1), 0.8% (v/v) bis (2:1), and 37% (v/v)
glycerol; resolving gel: 8% (v/v) acrylamide (40:1), 0.2% (v/v) bis
(2:1), and 37% (v/v) glycerol). Gels were run using a Minigel
system (Bio-Rad) at 4 °C, 160 V for 28 h (5–10 mA) with upper
and lower running buffer (100 mM Tris base, 150 mM glycine,
0.1% (w/v) SDS, pH 8.6; and 50 mM Tris base, 75 mM glycine,
0.05% SDS, respectively) at equal surface level. Gels were fixed
overnight in 10% acetic acid and 40% ethanol and stained using
the SilverQuestTM silver staining kit (Invitrogen). Images for
quantification were acquired by scanning the gels with a
GS-710 calibrated imaging densitometer (Bio-Rad), and the rel-
ative proportion of each MyHC isoform was determined using
Quantity 1 software (Bio-Rad). Bandswere identified according
to their migration characteristics, as described (22).
ElectronMicroscopy—For ultrastructural examination, white
gastrocnemius muscle samples were processed for electron
microscopic analysis. Skeletal muscle from Tg-AMPK3225Q
mice and nontransgenic littermates was perfused-fixed with
2.5% glutaraldehyde with 300 mM sucrose in 0.1 M cacodylate
buffer, pH7.2–7.4, dissected, cut into 1 1 2-mmpieces, and
fixed overnight. Samples were postfixed for 1 h in 1% (v/v)
osmium tetroxide, dehydrated through a graded series of alco-
hol/acetone, and embedded in Fluka Durcupan resin. Ultrathin
70-nmsectionswere placed on coppermesh grids (EMS), coun-
terstained with uranyl acetate and lead citrate, and examined
with a Morgagni 268 transmission electron microscope (FEI
Co., Hillsboro, OR). For quantification of percentage area of
mitochondria 10 random images/muscle were captured using
an AMT camera system (Advance Microscopy Techniques
Corp., Danvers, MA) at 20,400. Total mitochondrial volume
density, and number was determined.
Mitochondrial Respiration—Mitochondrial function was
assessed using respirometry (Oroboros Oxygraph-2k; Orobo-
ros Instruments, Innsbruck, Austria), as previously described
(23, 24). White gastrocnemius muscle was placed in a relaxing
solution (2.8 mM Ca2K2EGTA, 7.2 mM K2EGTA, 5.8 mM ATP,
6.6mMMgCl2, 20mM taurine, 15mM sodiumphosphocreatine,
20 mM imidazole, 0.5 mM dithiothreitol, and 50 mM MES, pH
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7.1), and fibers were gently separated under amicroscope using
fine forceps. Following permeabilization of the sarcolemma in
0.005% (w/v) saponin, the tissue was equilibrated in ice-cold
respirometry medium (0.5 mM EGTA, 3 mM MgCl2, 60 mM
potassium lactobionate, 20mM taurine, 10mMKH2PO4, 20mM
HEPES, 110mM sucrose, and 0.1% (w/v) bovine serum albumin,
pH 7.1) and blotted, and 1.5–2 mg of tissue/chamber was
weighed and used for the experiment. All measurements were
made in duplicate. Basal O2 flux from complex I (CI in Fig. 6) of
the respiratory chain was measured by adding the substrates
malate (final concentration 1.6 mM), glutamate (20 mM), and
pyruvate (9.8 mM). Oxidative phosphorylation was quantified
by the addition of ADP (4.8 mM), followed by the complex II
substrate succinate (9.6 mM), for convergent electron flow
through Complexes I  II. Then the protonophore carbonyl-
cyanide-4-(trifluoromethoxy)-phenylhydrazone (0.2 M) was
titrated to achieve maximum flux trough the electron transfer
system. Finally, electron transport through complexes I and III
was inhibited by the sequential addition of rotenone (0.1 M)
and antimycin A (2.4 M), respectively. The oxygen flux
obtained in each step of the protocol was normalized by mito-
chondrial content/nuclei as determined in the same muscle
using mitochondrial/nuclear DNA ratio (protocol detailed
above).
Statistical Analysis—Values are expressed as mean  S.E.
Statistically significant differences were determined using
unpaired Student’s t tests.
RESULTS
Skeletal Muscle Mitochondrial Content Is Unaltered in
Tg-AMPK3wt Mice—To ascertain whether overexpression of
the AMPK 3 subunit is sufficient to induce skeletal muscle
mitochondrial biogenesis, we studied sedentary mice overex-
pressing the wild-type form of the AMPK 3 subunit in glyco-
lytic muscle (Tg-AMPK3wt). ThemRNA expression profile of
different transcription factors and mitochondrial markers was
unaltered between Tg-AMPK3wt mice and nontransgenic lit-
termates (Fig. 1a). However, mRNA expression of the co-acti-
vator PGC-1 was reduced in skeletal muscle from
Tg-AMPK3wt mice. Protein content of several transcription
factors, markers of the different complexes of the respiratory
chain, and pyruvate dehydrogenase kinase 4 (PDK4), a key
enzyme in the regulation of substrate utilization and the switch
between glucose and fatty acid oxidation, was unaltered
between Tg-AMPK3wt mice and nontransgenic littermates
(Fig. 1, b and c). However, protein content of SDH ubiquinol
oxidoreductase (complex II of the respiratory chain) was
reduced in skeletal muscle from Tg-AMPK3wt mice (Fig. 1, b
and c). Muscle mitochondrial content and transverse sections
showing succinate dehydrogenase activity (SDH) were similar
between Tg-AMPK3wt mice and nontransgenic littermates
(Fig. 1, d and e). Thus, our results provide evidence to suggest
that increasing the amount of the AMPK 3 subunit is insuffi-
cient to induce mitochondrial adaptations in sedentary mice.
FIGURE 1. Skeletal muscle mitochondrial content is unaltered by AMPK 3 subunit overexpression. a, mRNA content of different transcription factors
responsible for mitochondrial biogenesis regulation and different mitochondrial markers in AMPK 3 subunit transgenic (Tg-AMPK3wt) mice (n  7) versus
nontransgenic (WT) littermates (n  7). b, Protein content of factors involved in mitochondrial biogenesis in Tg-AMPK3wt mice (n  8) and WT nontransgenic
littermates (n  7). c, representative immunoblots for the different proteins represented in Fig. 1b. d, mitochondrial content in gastrocnemius muscle from
Tg-AMPK3wt mice (n  7) and nontransgenic littermates (n  7). Mitochondrial content was estimated as the ratio between copy numbers of mtDNA
(cytochrome b) versus nuclear DNA (-actin). e, representative SDH activity in tranversal sections of white gastrocnemius muscle from Tg-AMPK3wt mice (n 
4) and nontransgenic littermates (n  4). Data are represented as mean  S.E. -fold change with respect to the corresponding nontransgenic littermates. Open
bar, nontransgenic WT; closed bar, Tg-AMPK3wt. *, p  0.05; significantly different from nontransgenic WT mice.
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Skeletal Muscle Mitochondrial Content Is Unaltered in
AMPK3/ Mice—To determine whether the AMPK 3 sub-
unit was required for resting skeletalmusclemitochondrial bio-
genesis, wemeasuredmRNAexpression and protein content of
mitochondrial markers as well as mitochondrial number in
AMPK3/ mice. mRNA content of different co-activators,
transcription factors, mitochondrial markers, and lipoprotein
lipase, a marker of fatty acid metabolism, were unaltered
between AMPK3/ mice and wild-type littermates. Protein
contents of PGC-1 and several mitochondrial markers were
unaltered between AMPK3/ and wild-type littermates.
Moreover, mitochondrial content and SDH staining were sim-
ilar between AMPK3/ and wild-type littermates (Fig. 2, d
and e).
Skeletal Muscle Mitochondrial Biogenesis Is Increased in
Tg-AMPK3225Q Mice—To determine whether mutations
in the AMPK 3 subunit increase mitochondrial biogenesis in
resting skeletalmuscle, we studied sedentarymice overexpress-
ing amutant form of the AMPK 3 subunit in glycolyticmuscle
(Tg-AMPK3225Q) and analyzed mRNA expression, protein
content, and mitochondrial number in skeletal muscle. We
assessed mRNA content of different co-activators and tran-
scription factors involved in the regulation of the mitochon-
drial biogenic process. PGC-1, NRF-1, NRF-2, and TFAM
mRNA content were significantly increased in Tg-AMPK3225Q
mice compared with nontransgenic littermates (Fig. 3a).
mRNA of several members of the fatty acid oxidative pathway
and other mitochondrial markers were increased in white gas-
trocnemius muscle from Tg-AMPK3225Q mice compared
with nontransgenic littermates (Fig. 3a). Protein content of
PGC-1, markers of the different complexes of the respiratory
chain, UCP3, and PDK4 were increased in gastrocnemius mus-
cles fromTg-AMPK3225Qmice comparedwith nontransgenic
littermates (Fig. 3, b and c). In contrast, protein expression
of the ATP synthase subunit  was unaltered between
Tg-AMPK3225Q and nontransgenic mice. Mitochondrial
content, as estimated by the relative content of mitochon-
drial DNA compared with nuclear DNA, was increased in
Tg-AMPK3225Q mice compared with nontransgenic litter-
mates (Fig. 3d). SDH staining, a marker of the oxidative profile
of individual fibers, was also increased in transversal sections of
white gastrocnemius muscle from Tg-AMPK3225Q mice (Fig.
3e), consistent with the increase in mitochondrial content.
Fiber Type Composition Is Unchanged in Tg-AMPK3225Q
Mice—Wenext assessedwhether the increase inmitochondrial
content in Tg-AMPK3225Q mice is due to alterations in the
skeletal muscle fiber type composition. Quantification of
ATPase enzyme activity by a histological approach revealed
that the percentage of type I, IIa, and IIb fibers in EDL, soleus
(Fig. 4, a and b), plantaris, and gastrocnemius (not shown) was
unaltered between Tg-AMPK3225Q mice and nontransgenic
littermates. Immunocytochemical staining with antibodies
against type I and type IIa fibers reveals a similar pattern (Fig.
4c).mRNAexpression ofMyHC I, IIa, IIb, and IIxwas unaltered
between the genotypes, and quantification of the same isoforms
following electrophoretic separation by glycerol-based SDS-
PAGE confirmed this finding at the protein level (Fig. 4, d and
e). These results provide evidence to suggest that the enhanced
FIGURE 2. Skeletal muscle mitochondrial content is unaltered in AMPK 3 knock-out (AMPK3/) mice. a, mRNA content of different transcription
factors responsible for mitochondrial biogenesis regulation and different mitochondrial markers in AMPK3/ mice (n  7) and homozygous WT littermates
(n  6). b, protein content of factors involved in mitochondrial biogenesis in AMPK3/ mice (n  8) and WT littermates (n  8). c, representative immunoblots
for the different proteins represented in Fig. 1b. d, mitochondrial content in gastrocnemius muscle from AMPK3/ mice (n  7) and homozygous WT
littermates (n  6). Mitochondrial content was estimated as the ratio between copy numbers of mtDNA (cytochrome b) versus nuclear DNA (-actin).
e, representative SDH staining of transversal sections of white gastrocnemius muscle from AMPK3/ mice (n  4) and homozygous WT littermates (n  4).
Data are represented as mean  S.E. -fold change with respect to the corresponding homozygous WT littermates. Open bar, homozygous WT; closed bar,
AMPK3/. *, p  0.05; significantly different from homozygous WT mice.
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mitochondrial biogenesis and metabolic adaptations in glyco-
lytic skeletal muscle of Tg-AMPK3225Q mice are unrelated to
fiber type reprogramming.
Skeletal Muscle Mitochondrial Total Area Is Increased in
Tg-AMPK3225QMice—To further characterizemitochondrial
adaptations in Tg-AMPK3225Q mice, we performed an ultra-
structural examination of white gastrocnemius muscle by elec-
tron microscopy (Fig. 5a). Total mitochondrial area was nor-
malized by the total area of each image and analyzed in 	30
images per genotype. A total of 700–900 mitochondria were
evaluated for each genotype. Mitochondrial area per total area
was 54% higher in Tg-AMPK3225Qmice versus nontransgenic
littermates (Fig. 5b). The increase in mitochondrial area could
be due to a highermitochondrial density (number ofmitochon-
dria) and/or an increase in the size of the mitochondria. Fea-
tures of mitochondrial dynamics, as assessed by the analysis of
the electron microscopic images, were observed in intermyofi-
brilar mitochondria of Tg-AMPK3225Q mice. We analyzed
more than 175mitochondrial aggregations per genotype (Fig. 5,
c and d). These observations are compatible with the increased
expression of different markers of mitochondrial dynamics,
including fusion, fission, and degradation in gastrocnemius
muscles fromTg-AMPK3225Qmice comparedwith nontrans-
genic littermates. MFN-2 (mitofusin 2), OPA-1 (dynamin-like
GTPase-optic atrophy 1), DRP-1 (dynamin-related protein 1),
and LonP (Lon protease) mRNA content was increased in
Tg-AMPK3225Q mice compared with nontransgenic litter-
mates (Fig. 5e). The increases in mRNA levels of fusion, fission,
and degradation proteins are similar to the changes observed in
other mitochondrial proteins and therefore might reflect the
increased mitochondrial mass.
Skeletal Muscle Mitochondrial Respiratory Control Is Unal-
tered in Tg-AMPK3225Q Mice—We next assessed mitochon-
drial function in permeabilized skeletal muscle fibers from
Tg-AMPK3225Q mice using high resolution respirometry to
measure electron transfer and respiratory control through
complex I (by adding malate, glutamate, and pyruvate) and/or
complex II (by supplying succinate). Excess ADP was added to
assess electron transfer coupled to oxidative phosphorylation.
The mitochondrial uncoupler carbonylcyanide-4-(trifluoro-
methoxy)-phenylhydrazone was added to reach maximal
capacity of the electron transfer system. Oxygen flux normal-
ized to skeletal muscle weight and mitochondrial content was
similar between Tg-AMPK3225Q mice and nontransgenic lit-
FIGURE 3. Skeletal muscle mitochondrial biogenesis is increased in Tg-AMPK3225Q mice. a, mRNA content of different transcription factors responsible
for mitochondrial biogenesis regulation and different mitochondrial markers in Tg-AMPK3225Q mice (n  9) and nontransgenic (WT) littermates (n  7).
b, protein content of mitochondrial biogenesis markers in Tg-AMPK3225Q mice (n  8) and nontransgenic littermates (n  8). c, representative immunoblots
for the different proteins represented in Fig. 1b. d, mitochondrial content in gastrocnemius muscle from Tg-AMPK3225Q mice (n  6) and nontransgenic
littermates (n  7). Mitochondrial content was estimated as the ratio between copy numbers of mtDNA (cytochrome b) versus nuclear DNA (-actin).
e, representative SDH activity of transversal sections of white gastrocnemius muscle from Tg-AMPK3225Q mice (n  4) and nontransgenic littermates (n  4).
Data are represented as mean  S.E. -fold change with respect to the corresponding nontransgenic WT littermates. Nontransgenic WT (open bar) and
Tg-AMPK3225Q (closed bar). *, p  0.05; significantly different from nontransgenic WT mice.
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termates (Fig. 6, a and b). Our results provide evidence to sug-
gest that mitochondrial performance is similar between
Tg-AMPK3225Q mice and nontransgenic littermates.
DISCUSSION
Here we show that a single nucleotide mutation (R225Q)
in the AMPK 3 subunit is associated with mitochondrial
biogenesis in glycolytic skeletal muscle, concomitant with
increased expression of the co-activator PGC-1 and several
transcription factors that regulate the expression of the dif-
ferent mitochondrial proteins. Overexpression or ablation of
the AMPK 3 subunit does not appear to play a critical role
in defining skeletal muscle mitochondrial content in resting
skeletal muscle, indicating that mutations in the AMPK 3
subunit, rather than changes in subunit expression, lead to
mitochondrial adaptations, possibly due to conformational
transformations that facilitate AMPK function (25, 26).
Most of the mutations described for the AMPK  regulatory
subunits are located near cystathionine b-synthase motifs
that generate two Bateman domains (27) and generally inter-
fere with the normal activation of AMPK by AMP (26). The
R225Q mutant form of the AMPK 3 subunit increases
AMPK phosphorylation in transfected COS cells (17) and
confers metabolic adaptations in
resting glycolytic skeletal muscle
that mimic endurance exercise
training (15, 16).
In Hampshire pigs, a naturally
occurring dominant mutation
(R200Q) was identified in the
AMPK 3 regulatory subunit that is
associated with increased skeletal
muscle glycogen content (28). Func-
tional analysis performed in skeletal
muscle-specific transgenic mice
expressing the mouse equivalent
(R225Q) mutation in the AMPK 3
subunit (Tg-AMPK3225Q mice)
reveal that this mutation increases
skeletal muscle glycogen content
(17, 18) and provides protection
from diet-induced insulin resist-
ance due to increased lipid oxida-
tion (17). The increase in skeletal
muscle glycogen in Tg-AMPK3225Q
mice is positively correlated with
work performance, indicating en-
hanced ergogenics (15). Our cur-
rent findings of increased skeletal
muscle mitochondrial content in
Tg-AMPK3225Q mice provide a
molecular basis for the increased
lipid oxidation and prevention of
diet-induced insulin resistance (17).
Imprinted and specialized meta-
bolic characteristics of skeletalmus-
cle fibers are established during dif-
ferentiation (29). The mechanism
by which skeletal muscle fiber differentiation leads to distinc-
tive metabolic phenotypes, as well as the ability of mature mus-
cle fibers to adapt to changes in energy demand, is complex and
incompletely resolved. Mitochondrial adaptations in skeletal
muscle can arise due to changes in specific genes (30–33).
Molecular approaches using transgenic technology reveal that
mice expressing an activated calcineurin under control of the
muscle creatine kinase enhancer exhibit an increase in oxida-
tive (slow twitch) skeletal muscle fibers (30) and mitochondrial
biogenesis (33). Overexpression of either the co-activator
PGC-1 or an activated form of the nuclear receptor PPAR
also leads to similar changes in mitochondrial biogenesis and
the oxidative capacity of skeletalmuscle, primarily due to a fiber
type transformation from glycolytic to oxidative fibers (31, 32).
However, in adult skeletal muscle, evidence supporting skeletal
muscle fiber type transformation, from glycolytic type II to oxi-
dative type I, in response to physiological perturbations, such as
exercise training, is lacking, since the greatest plasticity in the
exercise response is in the metabolic and enzymatic properties
of the fiber rather than the twitch potential (34, 35). In humans,
extreme ultraendurance exercise has little effect on fiber type
composition despite improvements in oxidative enzymes (36).
Even in extreme cases, such as cross-country ski training, where
FIGURE 4. Fiber type composition is unchanged in Tg-AMPK3225Q mice. a, representative pictures from
cross-sectional areas of soleus and EDL muscles from Tg-AMPK3225Q mice (n  4) and nontransgenic WT
littermates (n  5) for fiber type analysis, MyoATPase staining, pH 4.45. b, quantification of skeletal muscle fiber
types in soleus and EDL muscles based on MyoATPase staining, pH 4.45. c, representative image from cross-
sectional areas of soleus muscle from Tg-AMPK3225Q mice (n  4) and nontransgenic WT littermates (n  5)
mice after immunocytochemical staining with antibodies against type I (D5) and type IIa (SC71) fibers. d, MyHC
isoforms mRNA content in white gastrocnemius muscle from Tg-AMPK3225Q mice (n  9) and nontransgenic
WT littermates (n  7). e, representative silver staining of the different MyHC isoforms after electrophoretic
separation by glycerol-based SDS-PAGE in white gastrocnemius muscle from Tg-AMPK3225Q mice and non-
transgenic WT littermates. The first lane from the right is an experimental control showing different MyHC
isoform (types I, IIb, IIx, and IIa) in a pooled sample of soleus and EDL muscle homogenates (S  E). Data are
represented as mean  S.E. -fold change with respect to the corresponding nontransgenic WT littermates.
Open bar, nontransgenic WT; closed bar, Tg-AMPK3225Q.
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athletes also carry a backpack and pull a sledge 18.5 miles per
day for 6 days perweek for 8weeks, changes inmuscle fiber type
cannot fully account for the increased skeletal muscle oxidative
capacity andmitochondria biogenesis (37, 38). Thus, when one
considers the physiological response to exercise, which primar-
ily involves changes in oxidative enzymes and mitochondrial
biogenesis versusmany of the transgenic and knock-out mouse
models where fiber type changes arise presumably from devel-
opmental changes that reprogram the muscle phenotype, we
believe that the AMPK activation in this model may mimic the
physiological response to exercise. In this regard, the skeletal
muscle adaptations conferred by the R225Qmutant formof the
AMPK 3 subunit phenocopy the adaptive response to exercise
in humans, since changes in mitochondrial biogenesis was
observed independent of fiber type transformation. Different
regulatory processes could modify the imprinted characteris-
tics and adaptability of skeletal muscle fibers during develop-
mental stages and in the adult state.
Mitochondrial adaptations in skeletalmuscle can arise due to
AMPK genetic modifications in the  or  subunit (39–42).
Reductions in AMPK 2 activity due to aging are coupled to
reducedmitochondrial function, insulin resistance, and Type 2
diabetes (39). Moreover, mitochondrial protein expression in
resting AMPK 2 knock-out mice is reduced in skeletal muscle
(40), concomitant with a decrease in the maximal mitochon-
drial respiration in the heart (41). Similarly, PGC-1 protein
FIGURE 5. Mitochondrial area is increased in Tg-AMPK3225Q mice. Mitochondrial ultrastructure was examined in white gastrocnemius muscle from
Tg-AMPK3225Q mice (n  4) and nontransgenic WT littermates (n  4) by transmission electron microscopy. a, representative micrographs from muscle
specimens obtained from Tg-AMPK3225Q and nontransgenic WT mice. Scale bar, 1 M. b, percentage area of mitochondria was determined from images
captured at 20,400 with an area of 7.2 m2. Bars, mean  S.E. of all images counted from 30 – 40 individual images (total number of mitochondria measured
700 –900) per mouse strain. Area data are expressed in mitochondrial area per total image area. c, note that the mitochondria located between contractile units
in Tg-AMPK3225Q mice provide evidence of mitochondrial dynamics (larger mitochondria and aggregation of a higher number of mitochondria). d, quanti-
fication of mitochondrial aggregation as estimated by assessing more than 175 mitochondrial groups from white gastrocnemius muscle of Tg-AMPK3225Q
mice and nontransgenic WT mice. e, mRNA content of key regulators of mitochondrial dynamics (fusion: mitofusin 2 (MFN-2) and dynamin-like GTPase-optic
atrophy 1 (OPA-1); fission: dynamin-related protein 1 (DRP-1); and degradation: Lon protease (LonP) in Tg-AMPK3225Q mice and nontransgenic WT littermates.
Data are presented as mean  S.E.
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content and citrate synthase activity is reduced in skeletal mus-
cle-specific transgenic mice expressing the inactivating D157A
mutation in the AMPK 2 subunit (42). Thus, AMPK 2 iso-
form expression and total AMPK activity is important formito-
chondrial protein expression and the oxidative capacity. Con-
versely mitochondrial content is unaltered in AMPK3/ or
Tg-AMPK3wt mice, indicating that the 3 isoform does not
play a direct role.
Changes in AMPK activity conferred by the R225Q mutant
in the 3 subunit are likely to account for increased mitochon-
drial biogenesis. Consistent with this, PGC-1 protein content
and citrate synthase activity are increased in skeletal muscle-
specific transgenic mice expressing the activating R70Q muta-
tion in the AMPK 1 subunit (42). In contrast to the
Tg-AMPK3225Q mice, the proportion of glycolytic type IIa/x
fibers is increased in AMPK 1R70Q mice, compared with wild-
type littermates (42). These studies highlight the role of AMPK
in the regulation ofmitochondrial content and function in skel-
etal muscle. Polymorphisms in the AMPK 3 subunit in
humans do not seem to have an effect on glucose metabolism,
but two recently identified single nucleotide polymorphisms
(rs692243 and rs6436094) may play an important role in
lipoprotein metabolism (43). In humans, a homologous muta-
tion (AMPK 3R225W) increases AMPK activity and skeletal
muscle glycogen content, with a concomitant decrease in intra-
muscular triglyceride content (44). Collectively, these studies
reveal that distinct phenotypic adaptations are conferred by
specific AMPK subunits. The variation observed among the
different genetic modifications of AMPK subunits emphasizes
the importance of defining specialized roles of the different
AMPK subunit isoforms.
There are several potential mechanisms by which the R225Q
mutation in theAMPK 3 isoform can influencemitochondrial
biogenesis. TheAMPK 3 isoform can formheterotrimerswith
theAMPK2 and2 subunits in glycolytic skeletalmuscle (45).
AMPK activation increases mitochondrial enzymes in skeletal
muscle (3) by an AMPK 2-subunit dependent mechanism
(40). The AMPK 2 subunit and, presumably, heterotrimers
containing this subunit can be localized to the nucleus and
therefore can potentially directly phosphorylate transcription
factors to regulate gene expression (46). AMPK binds to and
activates PGC-1 in skeletal muscle by direct phosphorylation
on two critical residues, threonine 177 and serine 538 (7),
providing a potential mechanism for the effects of the muta-
tion on skeletal mitochondrial biogenesis. AMPK appears to
require PGC-1 for effects on GLUT4 and mitochondrial
gene expression in skeletal muscle (7). The mutations may
modify the nuclear localization of AMPK or the interaction
with PGC-1. Clearly, the mutated form of the AMPK 3
subunit leads to transcriptional changes that influence the
oxidative capacity of skeletal muscle fibers through
increased mitochondrial biogenesis.
The mechanism for the increase in mitochondria biogenesis
in theTg-AMPK3225Qmicemay involve increasedDNAbind-
ing of transcription factors, such as MEF (myocyte enhancer
factor). MEF2A, the predominant MEF2 gene product
expressed in postnatal cardiac muscle, plays a specific role in
maintaining appropriate mitochondrial content and cytoarchi-
tectural integrity (47). MEF2 interacts with the co-activator
PGC-1 (48) andNRF-1 to provide amechanism formitochon-
drial biogenesis regulation (49). In skeletal muscle, various fac-
tors, including insulin, hydrogen peroxide, osmotic stress,
contraction, and 5-aminoimidazole-4-carboxamide-1--D-ri-
bofuranoside, acutely increase MEF2 DNA binding (50, 51),
implicating insulin- and AMPK-dependent signaling path-
ways as playing a role. Compound C, an AMPK inhibitor, pre-
vents the acute 5-aminoimidazole-4-carboxamide-1--D-ribo-
furanoside-induced as well as contraction-inducedMEF2DNA
binding in skeletal muscle (50), providing pharmacological evi-
dence that action of AMPK is linked to MEF2 DNA binding.
These studies provide evidence that the effects of 5-aminoimi-
dazole-4-carboxamide-1--D-ribofuranoside and contraction
on MEF2 DNA binding are rapid and cannot be attributed to
changes in muscle fiber type composition. Thus, we cannot
exclude the possibility that AMPK-induced increases in
MEF2 DNA binding increase mitochondrial biogenesis in
Tg-AMPK3225Q mice. However, AMPK-activated increases
inMEF2DNAbinding have also been linked toGLUT4 biogen-
FIGURE 6. Skeletal muscle mitochondrial respiratory control is unaltered
in Tg-AMPK3225Q mice. Mitochondrial respiration was analyzed in perme-
abilized white gastrocnemius muscle samples and normalized by mitochon-
drial content. a, for basal (b) O2 flux from complex I (CI) of the respiratory chain
malate, glutamate, and pyruvate was added to the Oxygraph-2k chamber
(CIb). To maximize oxidative phosphorylation from complex I, ADP was added
in sufficient amounts to couple (c) electron transfer to ATP production (CIc).
To assess the combined oxidative phosphorylation activity (maximum cou-
pled respiration) of complex I and II, succinate was added (CI  IIc). To reach
maximal capacity of the electron transfer system (ETSI  II) by Complex I and II,
an uncoupler was added (protonophore carbonylcyanide-4-(trifluorome-
thoxy)-phenylhydrazone). Electron transport through complex I and II was
inhibited (i) by the sequential addition of rotenone (CIi) and antimycin A,
respectively. The remaining O2 flux after inhibition of complex I and III by
rotenone and antimycin A (O2 flux independent of the electron transfer sys-
tem) was subtracted from each of the previous steps. Mitochondrial content
was estimated as the ratio between copy numbers of mtDNA (cytochrome b)
versus nuclear DNA (-actin). b, respiratory control ratios, O2 fluxes (CIb, CIc, CI 
IIc, CIi, and CIIIi) normalized to electron transport system capacity (ETSI  II).
Data are presented as mean  S.E. for 16 –20 myofiber preparations from
8 –10 mice per genotype. Shown are WT (white columns) and Tg-AMPK3225Q
(black columns) mice.
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esis (50–54), but given that GLUT4 protein expression is unal-
tered in Tg-AMPK3225Q mice,3 an alternative mechanism for
the increase in mitochondria biogenesis warrants further con-
sideration. Our results suggest that the R225Qmutation in the
AMPK 3 promotes changes in signal transduction that
increase expression, and possibly activity, of PGC-1 and sev-
eral transcription factors that regulate mitochondrial biogene-
sis, including NRF-1, NRF-2, and TFAM.
In conclusion, the R225Qmutation in the AMPK 3 subunit
induces mitochondrial biogenesis in glycolytic skeletal muscle
independent of changes in fiber type composition. The rele-
vance of thismodification in theAMPK 3 isoform in glycolytic
skeletal muscle fibers highlights the potential role for AMPK to
modulate metabolic responses that influence whole body
metabolism. Pharmacological perturbation of the AMPK 3
isoform could be relevant for the treatment of metabolic
diseases.
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